Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study

Posted on by

Lancet Respiratory Medicine
Apr 2022 Volume 10 Number 4 p313-420, e34-e43
https://www.thelancet.com/journals/lanres/issue/current

 

Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study
Ruvim Izikson, et al.